Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02989844 · ClinicalTrials.gov registry record · Phase 2
Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02989844 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 20 participants.
The verdict
NCT02989844, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a single-arm, multi-center Phase II trial using IL-15 super-agonist complex (N-803 formerly known as Alt-803) maintenance after allogeneic hematopoietic cell transplant (alloHCT) for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).
Interventions
- DRUG N-803
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-04-12 |
| Est. Completion | 2022-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02989844
The ClinicalTrials.gov registry entry for NCT02989844 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which N-803 is the first listed.
NCT02989844 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02989844 about?
NCT02989844 is a clinical study titled "Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT". This is a single-arm, multi-center Phase II trial using IL-15 super-agonist complex (N-803 formerly known as Alt-803) maintenance after allogeneic hematopoietic cell transplant (alloHCT) for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).
What is the current status of trial NCT02989844?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2017-04-12. Estimated completion is 2022-08-31.
What interventions are being tested in trial NCT02989844?
The interventions under investigation include: N-803 (DRUG).
Who is sponsoring clinical trial NCT02989844?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.